|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-7-16
|
|
pubmed:abstractText |
ATIII is decreased in sepsis and/or shock and its baseline value correlates with mortality. The efficacy of ATIII therapy on mortality was assessed in a selected group of patients admitted to the intensive care unit (ICU) in a double-blind, randomized, multicenter study.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0342-4642
|
|
pubmed:author |
pubmed-author:ArlatiSS,
pubmed-author:BaudoFF,
pubmed-author:CaimiT MTM,
pubmed-author:CaloriGG,
pubmed-author:CarugoDD,
pubmed-author:CasellaGG,
pubmed-author:CrippaLL,
pubmed-author:D'AngeloAA,
pubmed-author:GallioliGG,
pubmed-author:GiudiciDD,
pubmed-author:LegnaniCC,
pubmed-author:PalaretiGG,
pubmed-author:RavizzaAA,
pubmed-author:RidolfiLL,
pubmed-author:RossiRR,
pubmed-author:WolflerAA,
pubmed-author:de CataldoFF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
336-42
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9609411-APACHE,
pubmed-meshheading:9609411-Aged,
pubmed-meshheading:9609411-Antithrombin III,
pubmed-meshheading:9609411-Double-Blind Method,
pubmed-meshheading:9609411-Female,
pubmed-meshheading:9609411-Humans,
pubmed-meshheading:9609411-Male,
pubmed-meshheading:9609411-Middle Aged,
pubmed-meshheading:9609411-Multiple Organ Failure,
pubmed-meshheading:9609411-Odds Ratio,
pubmed-meshheading:9609411-Postoperative Complications,
pubmed-meshheading:9609411-Proportional Hazards Models,
pubmed-meshheading:9609411-Sepsis,
pubmed-meshheading:9609411-Serine Proteinase Inhibitors,
pubmed-meshheading:9609411-Survival Analysis
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.
|
|
pubmed:affiliation |
Department of Hematology, Ospedale Niguarda, Milano, Italy. MD9821@mclink.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
